You are here

VENATORX PHARMACEUTICALS INC

Company Information
Address
30 SPRING MILL DR
MALVERN, PA 19355-1200
United States


https://www.venatorx.com

Information

UEI: MBBKNBU5DCC6

# of Employees: 70


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections

    Amount: $1,000,000.00

    PROJECT SUMMARY The emergence of SARS-CoV-2 in 2019 has resulted in an ongoing epidemic of acute respiratory illness that has stressed the world’s health care systems and led to rt6 million deaths. ...

    SBIRPhase II2023Department of Health and Human Services National Institutes of Health
  2. Discovery of antiviral inhibitors for the treatment of orthopoxvirus infections

    Amount: $300,000.00

    PROJECT SUMMARY Smallpox (caused by variola virus infection) was one of the most destructive diseases in human history, resulting in 300-500 million deaths in the twentieth century alone until it was ...

    SBIRPhase I2023Department of Health and Human Services National Institutes of Health
  3. Broad spectrum β-lactamase inhibitors employing a Trojan horse mechanism to rescue β-lactams against multidrug-resistant Pseudomonas aeruginosa

    Amount: $2,000,000.00

    Project Summary: Evolution of multiple resistance mechanisms from extensive use of antibiotics has eroded the efficacy of one of the most important classes of antibiotics, the β-lactams. The situatio ...

    SBIRPhase II2022Department of Health and Human Services National Institutes of Health
  4. Discovery of inhibitors that target HBx for the treatment of chronic HBV infection

    Amount: $506,623.00

    PROJECT SUMMARY The HBV X protein (HBx) represents an attractive target for drug discovery efforts as it plays a central role in activating viral gene expression and promoting conditions that allow th ...

    SBIRPhase I2021Department of Health and Human Services National Institutes of Health
  5. Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection

    Amount: $3,000,000.00

    PROJECT SUMMARY Despite the availability of a safe and effective vaccine, there remains over 257 million people chronicallyinfected with hepatitis B virus (HBV) world-wide. Individuals with chronic HB ...

    SBIRPhase II2021Department of Health and Human Services National Institutes of Health
  6. Discovery of antiviral inhibitors of Ebola virus replication

    Amount: $600,000.00

    Ebola viruses (EBOV) cause severe illnesses in humans with a high rate of mortality that approaches 90%. Novel therapies with potent and selective activity against EBOV are urgently needed for the pre ...

    SBIRPhase I2020Department of Health and Human Services National Institutes of Health
  7. Advancement of antiviral inhibitors of chikungunya virus

    Amount: $3,000,000.00

    PROJECT SUMMARY Novel therapies for the treatment of chikungunya virus (CHIKV) infections are urgently needed to address the alarming spread of this pathogen across the Americas. We have identified th ...

    SBIRPhase II2019Department of Health and Human Services National Institutes of Health
  8. Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas

    Amount: $3,000,000.00

    Project Summary This 3-year Phase II SBIR Application focuses on advancing the lead “ultra-broad-spectrum” carbapenem (USBC) VNRX-4099, possessing an unprecedented antibacterial spectrum of activi ...

    SBIRPhase II2018Department of Health and Human Services National Institutes of Health
  9. Discovery of inhibitors of Zika virus

    Amount: $599,998.00

    PROJECT SUMMARY Novel inhibitors of Zika virusZIKVare urgently needed to prevent the occurrence of virus induced microcephaly and Guillain BarrsyndromeThe objective of this Phase I SBIR feasibility st ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  10. Advancement to IND of novel BLI for pairing with cefixime

    Amount: $3,000,000.00

    Project Summary Abstractlactam antibiotics are the most widely used antibiotic class in the U Saccounting for more thanof antibacterial prescriptionsAmong other rolesthey are critical therapeutics for ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government